PL415967A1 - 5'-tiofosforanowe analogi końca 5' mRNA (kapu), sposób ich otrzymywania i zastosowanie - Google Patents
5'-tiofosforanowe analogi końca 5' mRNA (kapu), sposób ich otrzymywania i zastosowanieInfo
- Publication number
- PL415967A1 PL415967A1 PL415967A PL41596716A PL415967A1 PL 415967 A1 PL415967 A1 PL 415967A1 PL 415967 A PL415967 A PL 415967A PL 41596716 A PL41596716 A PL 41596716A PL 415967 A1 PL415967 A1 PL 415967A1
- Authority
- PL
- Poland
- Prior art keywords
- group
- independently selected
- alkyl
- dcps
- enzyme
- Prior art date
Links
- 108020004999 messenger RNA Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 101100438361 Drosophila melanogaster capu gene Proteins 0.000 title 1
- 101150087322 DCPS gene Proteins 0.000 abstract 3
- 102000004190 Enzymes Human genes 0.000 abstract 3
- 108090000790 Enzymes Proteins 0.000 abstract 3
- 101100386724 Schizosaccharomyces pombe (strain 972 / ATCC 24843) nhm1 gene Proteins 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- -1 OC2H5 Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 208000002320 spinal muscular atrophy Diseases 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- QNIZHKITBISILC-RPKMEZRRSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-methyloxolan-2-yl]-3h-purin-6-one Chemical compound C1=NC(C(NC(N)=N2)=O)=C2N1[C@]1(C)O[C@H](CO)[C@@H](O)[C@H]1O QNIZHKITBISILC-RPKMEZRRSA-N 0.000 abstract 1
- 102000009609 Pyrophosphatases Human genes 0.000 abstract 1
- 108010009413 Pyrophosphatases Proteins 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical group C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- 239000002516 radical scavenger Substances 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/02—Phosphorylation
- C07H1/04—Introducing polyphosphoric acid radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL415967A PL415967A1 (pl) | 2016-01-29 | 2016-01-29 | 5'-tiofosforanowe analogi końca 5' mRNA (kapu), sposób ich otrzymywania i zastosowanie |
| KR1020187021714A KR102742219B1 (ko) | 2016-01-29 | 2017-01-27 | 5'-포스포로티올레이트 mRNA 5'-말단 (캡) 유사체, 이를 포함하는 mRNA, 이를 얻기 위한 방법, 및 이의 용도 |
| EA201891429A EA038834B1 (ru) | 2016-01-29 | 2017-01-27 | 5'-фосфоротиоатные аналоги 5'-конца (кэпа) мрнк, содержащая их мрнк, способ их получения и применение |
| PCT/IB2017/050447 WO2017130151A1 (en) | 2016-01-29 | 2017-01-27 | 5'-phosphorothiolate mrna 5'-end (cap) analogs, mrna comprising the same, method of obtaining and uses thereof |
| CA3011663A CA3011663C (en) | 2016-01-29 | 2017-01-27 | 5'-phosphorothiolate mrna 5'-end (cap) analogs, mrna comprising the same, method of obtaining and uses thereof |
| PL17712541T PL3408276T3 (pl) | 2016-01-29 | 2017-01-27 | 5’-tiofosforanowe analogi końca 5’ mRNA (kapu), mRNA je zawierające, sposób ich otrzymywania i zastosowania |
| ES17712541T ES2879802T3 (es) | 2016-01-29 | 2017-01-27 | Análogos de extremo 5' (caperuza) de ARNm 5'-fosforotiolato, ARNm que comprende los mismos, método de obtención y usos de los mismos |
| JP2018537845A JP7144050B2 (ja) | 2016-01-29 | 2017-01-27 | ５’－ホスホロチオラート ｍＲＮＡ ５’－末端（キャップ）類似体、それを含むｍＲＮＡ、それらを得る方法およびそれらの使用方法 |
| EP17712541.6A EP3408276B1 (en) | 2016-01-29 | 2017-01-27 | 5'-phosphorothiolate mrna 5'-end (cap) analogs, mrna comprising the same, method of obtaining and uses thereof |
| AU2017211693A AU2017211693B2 (en) | 2016-01-29 | 2017-01-27 | 5'-phosphorothiolate mRNA 5'-end (cap) analogs, mRNA comprising the same, method of obtaining and uses thereof |
| US16/073,499 US11066436B2 (en) | 2016-01-29 | 2017-01-27 | 5′-phosphorothiolate mRNA 5′-end (cap) analogs, mRNA comprising the same, method of obtaining and uses thereof |
| CN201780013350.3A CN109071589A (zh) | 2016-01-29 | 2017-01-27 | 5′-硫代磷酸酯mRNA 5′-端(帽)类似物、包含所述类似物的mRNA、其获得方法和用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL415967A PL415967A1 (pl) | 2016-01-29 | 2016-01-29 | 5'-tiofosforanowe analogi końca 5' mRNA (kapu), sposób ich otrzymywania i zastosowanie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL415967A1 true PL415967A1 (pl) | 2017-07-31 |
Family
ID=58387852
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL415967A PL415967A1 (pl) | 2016-01-29 | 2016-01-29 | 5'-tiofosforanowe analogi końca 5' mRNA (kapu), sposób ich otrzymywania i zastosowanie |
| PL17712541T PL3408276T3 (pl) | 2016-01-29 | 2017-01-27 | 5’-tiofosforanowe analogi końca 5’ mRNA (kapu), mRNA je zawierające, sposób ich otrzymywania i zastosowania |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17712541T PL3408276T3 (pl) | 2016-01-29 | 2017-01-27 | 5’-tiofosforanowe analogi końca 5’ mRNA (kapu), mRNA je zawierające, sposób ich otrzymywania i zastosowania |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11066436B2 (enExample) |
| EP (1) | EP3408276B1 (enExample) |
| JP (1) | JP7144050B2 (enExample) |
| KR (1) | KR102742219B1 (enExample) |
| CN (1) | CN109071589A (enExample) |
| AU (1) | AU2017211693B2 (enExample) |
| CA (1) | CA3011663C (enExample) |
| EA (1) | EA038834B1 (enExample) |
| ES (1) | ES2879802T3 (enExample) |
| PL (2) | PL415967A1 (enExample) |
| WO (1) | WO2017130151A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE112020002327T5 (de) * | 2019-05-10 | 2022-07-14 | New England Biolabs, Inc. | Chemisches verkappen für matrizenwechsel |
| CN110907358B (zh) * | 2019-12-09 | 2022-08-30 | 福建师范大学 | 一种光微流微泡腔铅离子传感器的实现装置及方法 |
| PL432884A1 (pl) * | 2020-02-12 | 2021-08-16 | Uniwersytet Warszawski | Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu |
| CN113234780A (zh) * | 2020-08-20 | 2021-08-10 | 深圳市瑞吉生物科技有限公司 | 一种Cap2结构5′帽子类似物及其制备方法和应用 |
| CN116368226A (zh) | 2020-09-04 | 2023-06-30 | 维乎医疗有限公司 | 用于加帽rna的组合物和方法 |
| WO2023167880A2 (en) * | 2022-03-01 | 2023-09-07 | Verve Therapeutics, Inc. | Compositions and methods for capping rnas |
| CN114685588B (zh) * | 2022-05-05 | 2024-03-29 | 江苏申基生物科技有限公司 | 一种含开环核苷结构的起始加帽寡核苷酸引物 |
| CN116143855B (zh) * | 2022-11-08 | 2023-11-28 | 江苏申基生物科技有限公司 | 一种乙烯基膦酸修饰的mRNA帽类似物及其制备方法和应用 |
| EP4464713A1 (en) | 2023-05-18 | 2024-11-20 | Siec Badawcza Lukasiewicz - PORT Polski Osrodek Rozwoju Technologii | Circular rna analogs, preparation and application thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008546424A (ja) | 2005-06-28 | 2008-12-25 | アジェンコート パーソナル ジェノミクス コーポレイション | 修飾ポリヌクレオチドを作製する方法および配列決定する方法 |
| CN104072561B (zh) * | 2007-06-19 | 2017-12-22 | 路易斯安那州州立大学及农业机械学院管理委员会 | 信使rna帽的抗‑反向硫代磷酸类似物的合成和用途 |
| PL215513B1 (pl) * | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| EP2281579A1 (en) * | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| EP2970351B1 (en) * | 2013-03-14 | 2017-09-13 | Translate Bio, Inc. | Ribonucleic acids with 4'-thio-modified nucleotides and related methods |
| HRP20200250T1 (hr) | 2013-08-08 | 2020-05-29 | The Scripps Research Institute | Metoda site-specifično enzimsko obilježavanje nukleinskih kiselina in vitro ugradnjom neprirodnih nukleotida |
-
2016
- 2016-01-29 PL PL415967A patent/PL415967A1/pl unknown
-
2017
- 2017-01-27 ES ES17712541T patent/ES2879802T3/es active Active
- 2017-01-27 CA CA3011663A patent/CA3011663C/en active Active
- 2017-01-27 WO PCT/IB2017/050447 patent/WO2017130151A1/en not_active Ceased
- 2017-01-27 PL PL17712541T patent/PL3408276T3/pl unknown
- 2017-01-27 CN CN201780013350.3A patent/CN109071589A/zh active Pending
- 2017-01-27 EA EA201891429A patent/EA038834B1/ru unknown
- 2017-01-27 JP JP2018537845A patent/JP7144050B2/ja active Active
- 2017-01-27 EP EP17712541.6A patent/EP3408276B1/en active Active
- 2017-01-27 KR KR1020187021714A patent/KR102742219B1/ko active Active
- 2017-01-27 US US16/073,499 patent/US11066436B2/en active Active
- 2017-01-27 AU AU2017211693A patent/AU2017211693B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017211693B2 (en) | 2021-09-09 |
| US20190300563A1 (en) | 2019-10-03 |
| CA3011663A1 (en) | 2017-08-03 |
| JP2019504837A (ja) | 2019-02-21 |
| EP3408276B1 (en) | 2021-04-07 |
| AU2017211693A1 (en) | 2018-08-09 |
| ES2879802T3 (es) | 2021-11-23 |
| JP7144050B2 (ja) | 2022-09-29 |
| US11066436B2 (en) | 2021-07-20 |
| CA3011663C (en) | 2023-10-31 |
| EA038834B1 (ru) | 2021-10-26 |
| KR102742219B1 (ko) | 2024-12-13 |
| EA201891429A1 (ru) | 2019-02-28 |
| EP3408276A1 (en) | 2018-12-05 |
| CN109071589A (zh) | 2018-12-21 |
| WO2017130151A1 (en) | 2017-08-03 |
| PL3408276T3 (pl) | 2021-10-25 |
| KR20180100595A (ko) | 2018-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL415967A1 (pl) | 5'-tiofosforanowe analogi końca 5' mRNA (kapu), sposób ich otrzymywania i zastosowanie | |
| ZA202100208B (en) | Heterocyclic and heteroaryl compounds for treating huntington's disease | |
| PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
| MX2023001917A (es) | Inhibidores de la fosfatasa shp2 y metodos para su uso. | |
| MX2020014315A (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington. | |
| MX2020001598A (es) | Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5). | |
| GEP20257823B (en) | Amino quinazoline derivatives as p2x3 inhibitors | |
| CU20190045A7 (es) | Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas que son inhibidores de la dihidroorotato deshidrogenasa (dhodh) útiles para el tratamiento o prevención de trastornos hiperproliferativos e inflamatorios | |
| EP4424315A3 (en) | Novel compounds | |
| UA109220C2 (uk) | Похідні (4-фенілімідазол-2-іл)етиламіну як модулятори натрієвих каналів | |
| HK1252623A1 (zh) | 可用作TNFα调节剂的杂环化合物 | |
| EA201991183A1 (ru) | Новые ингибиторы глутаминазы | |
| AR066958A1 (es) | Imidazopirazinas como inhibidores de proteina quinasa | |
| EA201990904A1 (ru) | 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы | |
| EA201891379A1 (ru) | Ингибиторы тирозинкиназы брутона и способы их применения | |
| MY162167A (en) | Substituted acetyl-coa carboxylase inhibitors | |
| MX336711B (es) | Inhibidores de catecol o-metil transferasa y su uso en el tratamiento de transtornos psicoticos. | |
| JO3794B1 (ar) | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون | |
| JOP20190262B1 (ar) | مثبطات بيرازول magl | |
| EA201300436A1 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| ZA202304541B (en) | Cdk inhibitors and their use as pharmaceuticals | |
| ZA202005325B (en) | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) | |
| PH12022550843A1 (en) | Thienopyrimidones as trpa1 inhibitors | |
| EA202190058A1 (ru) | Композиции фосфорамидатных производных нуклеозидных лекарственных средств | |
| MX2017011577A (es) | Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf). |